Morgan Joseph Reiterates a 'Buy' on BioMarin Pharmaceutical (BMRN)
More News related to BMRN
- BioMarin to Present at the NASDAQ OMX 23rd Investor Program
- BioMarin (BMRN) Responds to News of Contamination at Genzyme (GENZ) Plant; Says Aldurazyme, Naglazyme Won't Be Impacted
- Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme
- United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food
- BioMarin to Present at the Credit Suisse Healthcare Conference
More News related to Analyst Comments
- Davenport Upgrades Heinz (HNZ) to Buy
- First Analysis Upgrades Advisory Board Company (ABCO) to Overweight
- Jefferies & Co Upgrades Energy XXI (EXXI) to Hold
- Morgan Stanley Upgrades Iowa Telecom (IWA) to Equalweight
- Fox-Pitt Upgrades Eaton Vance (EV) to Outperform
Morgan Joseph reiterates a 'Buy' rating on BioMarin Pharmaceutical (Nasdaq: BMRN), price target $20.
Morgan analyst says, "Although the possibility of additional acquisitions could prevent near-term outperformance, our long-term thesis remains unchanged: We expect BioMarin's top line, driven by four growing drugs, to improve margins over the next few years. We believe that BioMarin will be able to generate one additional drug during the next 5 years to drive the company's margins towards the
average of profitable biotechs."
To see more analyst ratings on BMRN Click Here.
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions.
Related Categories
Analyst CommentsStocks Mentioned
+0.10Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
